MENLO PARK, Calif.--(BUSINESS WIRE)--Refuge Biotechnologies, Inc. ("Refuge"), a synthetic biology company developing intelligent cell therapeutics for cancer immunotherapy, today announced that Bing Wang, Ph.D., Co-Founder and Chief Executive Officer of Refuge, is scheduled to present at the 2019 Cantor Fitzgerald Global Healthcare Conference on Friday, October 4, 2019 at 8:55 AM ET.
A live audio webcast will be accessible in the media section of the company’s website at www.refugebiotech.com. A replay of the webcast will be archived on the company’s website for 40 days.
About Refuge Biotechnologies
Refuge Biotechnologies is a synthetic biology company developing intelligent cell therapeutics for cancer immunotherapy. Refuge's proprietary receptor-dCas platform leverages a unique gene engineering approach based on precision CRISPR activation (CRISPRa) and CRISPR interference (CRISPRi). By connecting ligand specific receptors to dCas, Refuge enables cells to sense its surroundings and conditionally activate or repress multiple genes when they encounter specific external antigens. In particular, with receptor-dCas, immune cells can now be engineered to conditionally turn on/off certain genes, such as PD-1, to generate more potent CAR-T immune cells when it senses the presence of a tumor cell. For further information, please visit www.refugebiotech.com.